Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally
Biochemical and Biophysical Research Communications · 2023-02 · 645 · 132-136
DOI: 10.1016/j.bbrc.2023.01.040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2023-02. Verfasst von Sho Kawashima und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd., 1-1, Futaba-cho 3-chome, Toyonaka, Osaka, 561-0825, Japan. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shionogi.
Abstract (Originalsprache)
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a public health concern worldwide. Ensitrelvir (S-217622) has been evaluated as an antiviral treatment for COVID-19, targeting SARS-CoV-2 3C-like protease (3CLpro). Ensitrelvir has been reported to have comparable antiviral activity against some of the SARS-CoV-2 variants: alpha, beta, gamma, delta, and omicron (BA.1.18). In this paper, we describe that ensitrelvir is effective against newly emerging SARS-CoV-2 variants and globally prevalent 3CLpro mutations. Ensitrelvir exhibited comparable antiviral activity against SARS-CoV-2 variants, including recently emerging ones: omicron (BA1.1, BA.2, BA.2.75, BA.4, BA.5, BQ.1.1, XBB.1, and XE), mu, lambda, and theta. Genetic surveillance of SARS-CoV-2 3CLpro, the target of ensitrelvir, was conducted using a public database and identified 11 major 3CLpro mutations circulating globally (G15S, T21I, T24I, K88R, L89F, K90R, P108S, P132H, A193V, H246Y, and A255V). The 3CLpro mutation from proline to histidine at amino acid position 132 was especially identified in the omicron variant, with prevalence of 99.69%. Enzyme kinetic assay revealed that these 3CLpro mutants have enzymatic activity comparable to that of the wild type (WT). Next, we assessed the inhibitory effect of ensitrelvir against mutated 3CLpro, with it showing inhibitory effects similar to that against the WT. These in vitro data suggest that ensitrelvir will be effective against currently circulating SARS-CoV-2 variants, including omicron variants and those carrying 3CLpro mutations, which emerging novel SARS-CoV-2 variants could carry.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd., 1-1, Futaba-cho 3-chome, Toyonaka, Osaka, 561-0825, Japan.
- Laboratory for Bio-Drug Discovery, Shionogi & Co., Ltd., 1-1, Futaba-cho 3-chome, Toyonaka, Osaka, 561-0825, Japan.
- Shionogi TechnoAdvance Research CO., LTD., 1-1, Futaba-cho 3-chome, Toyonaka, Osaka, 561-0825, Japan.
- Laboratory for Medicinal Chemistry Research, Shionogi & Co., Ltd., 1-1, Futaba-cho 3-chome, Toyonaka, Osaka, 561-0825, Japan.
- Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd., 1-1, Futaba-cho 3-chome, Toyonaka, Osaka, 561-0825, Japan. Electronic address: teruhisa.kato@shionogi.co.jp.
Förderung
- Shionogi
Zitieren
APA
Kawashima, S., Matsui, Y., Adachi, T., Morikawa, Y., Inoue, K., Takebayashi, S., Nobori, H., Rokushima, M., Tachibana, Y., & Kato, T. (2023). Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally. Biochemical and Biophysical Research Communications, 645, 132-136. https://doi.org/10.1016/j.bbrc.2023.01.040
Vancouver
Kawashima S, Matsui Y, Adachi T, Morikawa Y, Inoue K, Takebayashi S, et al. Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally. Biochemical and Biophysical Research Communications. 2023;645:132-136. doi:10.1016/j.bbrc.2023.01.040
BibTeX
@article{Kawashima2023,
author = {Kawashima, Sho and Matsui, Yuki and Adachi, Takumi and Morikawa, Yuji and Inoue, Kae and Takebayashi, Shiori and Nobori, Haruaki and Rokushima, Masatomo and Tachibana, Yuki and Kato, Teruhisa},
title = {Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally},
journal = {Biochemical and Biophysical Research Communications},
year = {2023},
volume = {645},
pages = {132--136},
doi = {10.1016/j.bbrc.2023.01.040}
}
EUVIMED